Clinical Trial Update: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating Darzalex Faspro (daratumumab and hyaluronidase-fihj) given before desensitization and allogeneic stem cell transplantation in ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Aplastic Anemia
• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Hematologic Malignancy, Bone Marrow Transplant Rejection | EARLY_Phase 1 | Status: RECRUITING